Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.70
DSCO's Cash to Debt is ranked lower than
58% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. DSCO: 1.70 )
Ranked among companies with meaningful Cash to Debt only.
DSCO' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 1.7

Equity to Asset 0.21
DSCO's Equity to Asset is ranked lower than
51% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.24 vs. DSCO: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
DSCO' s 10-Year Equity to Asset Range
Min: -3.25   Max: 0.93
Current: 0.21

-3.25
0.93
F-Score: 5
Z-Score: -20.82
M-Score: -22.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1458.03
DSCO's Operating margin (%) is ranked higher than
51% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1702.36 vs. DSCO: -1458.03 )
Ranked among companies with meaningful Operating margin (%) only.
DSCO' s 10-Year Operating margin (%) Range
Min: -619900   Max: -834.65
Current: -1458.03

-619900
-834.65
Net-margin (%) -1494.52
DSCO's Net-margin (%) is ranked higher than
50% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1412.53 vs. DSCO: -1494.52 )
Ranked among companies with meaningful Net-margin (%) only.
DSCO' s 10-Year Net-margin (%) Range
Min: -920000   Max: -850.13
Current: -1494.52

-920000
-850.13
ROE (%) -155.43
DSCO's ROE (%) is ranked lower than
63% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -61.96 vs. DSCO: -155.43 )
Ranked among companies with meaningful ROE (%) only.
DSCO' s 10-Year ROE (%) Range
Min: -575.17   Max: -65.45
Current: -155.43

-575.17
-65.45
ROA (%) -76.41
DSCO's ROA (%) is ranked lower than
64% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -39.06 vs. DSCO: -76.41 )
Ranked among companies with meaningful ROA (%) only.
DSCO' s 10-Year ROA (%) Range
Min: -186.83   Max: -56.04
Current: -76.41

-186.83
-56.04
ROC (Joel Greenblatt) (%) -2358.14
DSCO's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: -1309.62 vs. DSCO: -2358.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DSCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2627.27   Max: -263.79
Current: -2358.14

-2627.27
-263.79
EBITDA Growth (3Y)(%) -19.70
DSCO's EBITDA Growth (3Y)(%) is ranked higher than
72% of the 1055 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DSCO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55   Max: 22.5
Current: -19.7

-55
22.5
EPS Growth (3Y)(%) -17.60
DSCO's EPS Growth (3Y)(%) is ranked higher than
75% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: -17.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DSCO' s 10-Year EPS Growth (3Y)(%) Range
Min: -61.7   Max: 25.5
Current: -17.6

-61.7
25.5
» DSCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

DSCO Guru Trades in Q2 2013

Jim Simons 12,392 sh (New)
» More
Q3 2013

DSCO Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2014

DSCO Guru Trades in Q1 2014

George Soros 166,400 sh (New)
» More
Q2 2014

DSCO Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DSCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.10
DSCO's P/B is ranked lower than
78% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 9.10 )
Ranked among companies with meaningful P/B only.
DSCO' s 10-Year P/B Range
Min: 1.51   Max: 68
Current: 9.1

1.51
68
P/S 23.61
DSCO's P/S is ranked lower than
64% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 23.61 )
Ranked among companies with meaningful P/S only.
DSCO' s 10-Year P/S Range
Min: 19.17   Max: 5370
Current: 23.61

19.17
5370
Current Ratio 3.91
DSCO's Current Ratio is ranked higher than
60% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.70 vs. DSCO: 3.91 )
Ranked among companies with meaningful Current Ratio only.
DSCO' s 10-Year Current Ratio Range
Min: 0.35   Max: 19
Current: 3.91

0.35
19
Quick Ratio 3.91
DSCO's Quick Ratio is ranked higher than
60% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. DSCO: 3.91 )
Ranked among companies with meaningful Quick Ratio only.
DSCO' s 10-Year Quick Ratio Range
Min: 0.35   Max: 19
Current: 3.91

0.35
19
Days Inventory 25.55
DSCO's Days Inventory is ranked higher than
94% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 25.55 )
Ranked among companies with meaningful Days Inventory only.
DSCO' s 10-Year Days Inventory Range
Min: 9.5   Max: 2464.8
Current: 25.55

9.5
2464.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.70
DSCO's Price/Net Cash is ranked higher than
82% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 13.70 )
Ranked among companies with meaningful Price/Net Cash only.
DSCO' s 10-Year Price/Net Cash Range
Min: 1.2   Max: 148.13
Current: 13.7

1.2
148.13
Price/Net Current Asset Value 13.70
DSCO's Price/Net Current Asset Value is ranked higher than
80% of the 1061 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 13.70 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DSCO' s 10-Year Price/Net Current Asset Value Range
Min: 0.49   Max: 149
Current: 13.7

0.49
149
Price/Tangible Book 9.10
DSCO's Price/Tangible Book is ranked higher than
66% of the 1039 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: 9.10 )
Ranked among companies with meaningful Price/Tangible Book only.
DSCO' s 10-Year Price/Tangible Book Range
Min: 0.48   Max: 62.85
Current: 9.1

0.48
62.85
Price/Median PS Value 0.10
DSCO's Price/Median PS Value is ranked higher than
100% of the 1065 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. DSCO: 0.10 )
Ranked among companies with meaningful Price/Median PS Value only.
DSCO' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 13.99
Current: 0.1

0.01
13.99
Earnings Yield (Greenblatt) -77.80
DSCO's Earnings Yield (Greenblatt) is ranked lower than
93% of the 1057 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DSCO: -77.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
DSCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -77.8   Max: 1813985.5
Current: -77.8

-77.8
1813985.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DYBN.Germany,
Discovery Laboratories Inc was incorporated as a Delaware corporation in 1992. The Company is a specialty biotechnology company engaged in creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Its proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. The Company is developing its KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. IT is also developing novel drug delivery technologies potentially to enable efficient delivery of its aerosolized KL4 surfactant. The Company is initially engaged in improving the management of respiratory distress syndrome (RDS) in premature infants. It has developed a disposable aerosol-conducting airway connector for infants that is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care patients requiring ventilatory support. The Company has exclusive rights to its CAG technology for use with pulmonary surfactants for all respiratory diseases and conditions. In addition, it hold in the U.S. exclusive rights to the CAG technology for use with certain non-surfactant drugs to treat various pediatric and adult respiratory indications in hospitals and other health care institutions. It has also developed a novel, disposable aerosol-conducting airway connector that is intended to simplify the delivery of aerosolized medications, including its aerosolized KL4 surfactant, and inhaled therapies to infants requiring ventilatory support in the NICU and PICU. AEROSURF, AFECTAIR, AFECTAIR DUO, DISCOVERYLABS, SURFAXIN, SURFAXIN LS, and WARMING CRADLE are the Company's registered and common law trademarks. The Company's development, manufacture, distribution, marketing and advertising of drug, device, and combination drug-device products are subject to extensive regulation by federal, state and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for DSCO

Headlines

Articles On GuruFocus.com
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q/A) Nov 15 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 10 2010 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Nov 09 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) Aug 10 2009 
Discovery Laboratories Inc. Reports Operating Results (10-Q) May 12 2009 

More From Other Websites
DISCOVERY LABORATORIES INC /DE/ Financials May 20 2015
Discovery Labs Announces Enrollment of First Patient in AEROSURF® Phase 2a Dose Expansion Trial May 20 2015
Discovery Labs Announces Enrollment of First Patient in AEROSURF® Phase 2a Dose Expansion Trial May 20 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 15 2015
Discovery Labs Announces Results of Phase 2a Clinical Trial of AEROSURF® May 14 2015
10-Q for Discovery Laboratories, Inc. May 13 2015
Discovery Labs to Announce Results from AEROSURF® Phase 2a Clinical Trial May 13 2015
Discovery Labs to Announce Results from AEROSURF® Phase 2a Clinical Trial May 13 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 10-Q, Quarterly Report May 11 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... May 08 2015
Discovery Laboratories reports 1Q loss May 07 2015
Discovery Laboratories reports 1Q loss May 07 2015
Discovery Labs Reports First Quarter 2015 Financial Results May 07 2015
10-K for Discovery Laboratories, Inc. May 04 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Termination of a Material Definitive Agreement,... Apr 16 2015
Discovery Labs Completes Enrollment of AEROSURF® Phase 2a Clinical Trial and Restructures its... Apr 16 2015
Discovery Labs Completes Enrollment of AEROSURF® Phase 2a Clinical Trial and Restructures its... Apr 16 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers Mar 31 2015
Market Has Not Yet Noticed Potential in Discovery Laboratories (DSCO); Have You? - Tale of the Tape Mar 31 2015
DISCOVERY LABORATORIES INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK